SPXA — SpectrumDNA Income Statement
0.000.00%
FinancialsHighly SpeculativeMicro Cap
- $0.00m
- -$0.00m
- $0.14m
Annual income statement for SpectrumDNA, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2006 December 31st | 2007 December 31st | 2008 December 31st | C2009 December 31st | 2010 December 31st | |
---|---|---|---|---|---|
Period Length: | 8 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0.054 | 0.068 | 0.15 | 0.141 |
Cost of Revenue | |||||
Gross Profit | 0 | 0.01 | -0.03 | 0.095 | 0.137 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 0.34 | 1.96 | 2.66 | 2.56 | 2.07 |
Operating Profit | -0.34 | -1.91 | -2.6 | -2.41 | -1.92 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -0.302 | -1.83 | -2.56 | -2.47 | -1.97 |
Provision for Income Taxes | |||||
Net Income After Taxes | -0.302 | -1.83 | -2.56 | -2.47 | -1.97 |
Net Income Before Extraordinary Items | |||||
Net Income | -0.302 | -1.83 | -2.56 | -2.47 | -1.97 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -0.302 | -1.83 | -2.56 | -2.47 | -1.97 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.008 | -0.039 | -0.053 | -0.05 | -0.029 |
Dividends per Share |